BECLABUVIR

Possibly Marketed Outside US

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C36H45N5O5S
Molecular Weight	659.838
Optical Activity	UNSPECIFIED
Defined Stereocenters	4 / 4
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

COC1=CC=C2C3=C(C4CCCCC4)C5=CC=C(C=C5N3C[C@]6(C[C@H]6C2=C1)C(=O)N7[C@H]8CC[C@@H]7CN(C)C8)C(=O)NS(=O)(=O)N(C)C

InChI

InChIKey=ZTTKEBYSXUCBSE-QDFUAKMASA-N

InChI=1S/C36H45N5O5S/c1-38(2)47(44,45)37-34(42)23-10-14-28-31(16-23)40-21-36(35(43)41-24-11-12-25(41)20-39(3)19-24)18-30(36)29-17-26(46-4)13-15-27(29)33(40)32(28)22-8-6-5-7-9-22/h10,13-17,22,24-25,30H,5-9,11-12,18-21H2,1-4H3,(H,37,42)/t24-,25+,30-,36-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C36H45N5O5S
Molecular Weight	659.838
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	4 / 4
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/30848363 | https://www.hepmag.com/pdfs/hepatitis_c_drug_list.pdf

Beclabuvir (previously known as BMS-791325), a potent, non-nucleoside inhibitor of the HCV NS5B RNA polymerase. In combination with daclatasvir and asunaprevir drug participates in clinical trials phase III for patients infected with HCV genotype 1, which is the most common genotype worldwide. Recently published data has shown that this combination achieved very high rates of viral eradication.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Hepatitis C virus NS5B RNA-dependent RNA polymerase 14 Target ID: CHEMBL5375 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24733465	Inhibitor 8504		0.003 µM [IC50]

PubMed

Title	Date	PubMed
Beclabuvir in combination with asunaprevir and daclatasvir for hepatitis C virus genotype 1 infection: A systematic review and meta-analysis.	2018-05	28892235
Effects of a Fixed-Dose Co-Formulation of Daclatasvir, Asunaprevir, and Beclabuvir on the Pharmacokinetics of a Cocktail of Cytochrome P450 and Drug Transporter Substrates in Healthy Subjects.	2018-03	29255971
A randomized, placebo-controlled study of the NS5B inhibitor beclabuvir with peginterferon/ribavirin for HCV genotype 1.	2015-08	25496007
Beclabuvir for the treatment of hepatitis C.	2015	26156630

Patents

Sample Use Guides

In Vivo Use Guide

Oral treatment with Asunaprevir 200mg (ASV), Daclatasvir 30 mg (DCV) and BMS-791325 75 mg in a fixed dose combination pill (FDC), twice daily, for 12 weeks in HIV/HCV genotype 1a or 1b patients Other Name: Asunaprevir (ASV) and Daclatasvir (DCV) and BMS-791325 (Beclabuvir)

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Mon Mar 31 21:34:54 GMT 2025` Edited by `admin` on `Mon Mar 31 21:34:54 GMT 2025`
Record UNII	MYW1X5CO9S
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

BECLABUVIR

Official Name

English

beclabuvir [INN]

Preferred Name

English

BMS-791325

Code

English

(4bS,5aR)-12-Cyclohexyl-N-(dimethylsulfamoyl)-3-methoxy-5a-[(3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl]-4b,5,5a,6-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-9-carboxamide

Systematic Name

English

CYCLOPROP(D)INDOLO(2,1-A)(2)BENZAZEPINE-9-CARBOXAMIDE, 12-CYCLOHEXYL-N-((DIMETHYLAMINO)SULFONYL)-4B,5,5A,6-TETRAHYDRO-3-METHOXY-5A-((3-METHYL-3,8-DIAZABICYCLO(3.2.1)OCT-8-YL)CARBONYL)-, (4BS,5AR)-

Systematic Name

English

BECLABUVIR [USAN]

Common Name

English

Beclabuvir [WHO-DD]

Common Name

English

BECLABUVIR [MI]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C783